Of mice and (wo)men: Mouse models of breast cancer metastasis to bone

Journal of Bone and Mineral Research

Volumn 25, Issue 3, 2010, Pages 431-436

  Goldstein, Robert H ^a   Weinberg, Robert A ^b   Rosenblatt, Michael ^a,c  

^a TUFTS UNIVERSITY   (United States)

^b WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; PARATHYROID HORMONE RELATED PROTEIN; TRANSCRIPTION FACTOR RUNX2; VASCULOTROPIN;

BONE CANCER; BONE METASTASIS; BREAST CANCER; CARCINOGENESIS; DEMINERALIZATION; HUMAN; IMMUNOCOMPETENCE; METASTASIS; NONHUMAN; OSTEOCLAST; PROSTATE CANCER; PROTEIN SECRETION; REVIEW; XENOGRAFT; ANIMAL; BONE TUMOR; BREAST TUMOR; DISEASE MODEL; FEMALE; MOUSE; PATHOPHYSIOLOGY; SECONDARY;

ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE;

EID: 77953366718     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.68     Document Type: Review

References (75)

1. Jermal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2. Coleman RE. Future directions in the treatment and prevention of bone metastases. Am J Clin Oncol. 2002;25:S32-38.
3. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584-593.
4. Diel IJ, Solomayer EF, Bastert G. Treatment of metastatic bone disease in breast cancer: bisphosophonates. Clin Breast Cancer. 2000;1: 43-51.
5. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655-1664.
6. Rubens RD. The nature of metastatic bone disease. In: Rubens RD, Fogelman I, eds. Bone Metastases: Diagnosis and Treatment. London: Springer-Verlag; 1992: 1-10.
7. Parsons JT, Zetter B, Mohla S. Shifting paradigms in tumor metastasis: challenges and opportunities. Cancer Biol Ther. 2002;1:582-585.
8. Lelekakis M, Moseley JM, Martin TJ, et al. A Novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis. 1999;17:163-170.
9. Sasaki A, Boyce BF, Story B, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 1995;51995;5:3551-3557.
10. Mbalaviel G, Dunsan CR, Sasaki A, William PJ, Mundy GR, Yoneda T. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in experimental metastasis model. Cancer Res. 1996;56:4063-4070. (Pubitemid 26284761)
11. Kang Y, Siegel P, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3:537-549. (Pubitemid 36808649)
12. Nemeth JA, Harb JF, Barroros U Jr, He Z, Grignon DJ, Cher ML. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res. 1999l;59:1987-1993.
13. Shtivelman E, Namikawa R. Species-specific metastasis of human tumor cells in the sever combined immunodeficiency mouse engrafted with human tissue. Proc Natl Acad Sci USA. 1995;92: 4661-4665.
14. Yonou H, Yokose T, Kamijo T, et al. Establishment of a novel species-and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/sever combined immunodeficient mice engrafted with human lung and bone. Cancer Res. 2001;61: 2177-2182. (Pubitemid 32692044)
15. Kuperwasser C, Dessain S, Bierbaum BE, et al. A mouse model of human breast cancer metastasis to human bone. Cancer Res. 2005;65:6130-6138. (Pubitemid 40994398)
16. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 2002;52:1399-1405.
17. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2:563-572. (Pubitemid 37328923)
18. Fidler IJ. The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nat Rev Cancer. 2003;3:453-458.
19. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nature. 2008;8:329-340. (Pubitemid 351596394)
20. Yoneda T. Cellular and molecular basis of preferential metastasis of breast cancer to bone. J Orthop Sci. 2000;5:75-81. (Pubitemid 30133795)
21. Rodan GA. The development and function of the skeleton and bone metastases. Cancer. 2003;97:726-732.
22. Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun. 2005;328:679-687.
23. Weber MH, Goltzman D, Kosternuik P, et al. Mechanisms of tumor metastasis to bone. Crit Rev Eukaryot Gene Expr. 2000;10:281-302.
24. Goltzman D. Osteolysis and cancer. J Clin Invest. 2001;107:1219-1220.
25. Bäuerie T, Adwan H, Kiessling F, Hilbig H, Armbruster FP, Berger MR. Characterization of a rat model with site-specific bone metastasis induced by MDA-MB-231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein. Int J Cancer. 2005;115:177-186.
26. Käkönen SM, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer. 2003;97:834-839.
27. Sloan EK, Anderson RL. Genes involved in breast cancer metastasis to bone. Cell Mol Life Sci. 2002;59:1491-1502.
28. Noti JD. Adherence to osteopontin via alphavbeta3 suppresses phorbol ester-mediated apoptosis in MCF-7 breast cancer cells that overexpress protein kinase Cα. Int J Oncol. 2000;17:1237-1243.
29. Waltregny D, Bellahcéne A, de Leval X, Florkin B, Weidle U, Castronovo V. Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. J Bone Miner Res. 2000;15:834-843.
30. Ibrahim T, Leong I, Sanchez-Sweatman O, et al. Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin Exp Metastasis. 2000;18:253-260.
31. Bellahcéne A, Castronovo V. Expression of bone matrix proteins in human breast cancer: potential roles in microcalcification formation and in the genesis of bone metastases. Bull Cancer. 1997;84:17-24.
32. Fata JE, Kong YY, Li J, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell. 2003;103:41-50.
33. Javed A, Barnes GL, Pratap J, et al. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Scie USA. 2005;102: 1454-1459.
34. Barnes GL, Hebert KE, Kamal M, et al. Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastasis-associated osteolytic disease. Cancer Res. 2004;64:4506-4513.
35. Shore P. A role for Runx2 in normal mammary gland and breast cancer bone metastasis. J Cell Biochem. 2005;96:484-489.
36. Hunt NC, Fjikawa Y, Sabokbar A, Itonaga I, Harris A, Athanasou NA. Cellular mechanisms of bone resorption in breast carcinoma. Br J Cancer. 2001;85:78-84.
37. Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr. 2000;10:159-178.
38. Lindemann RK, Ballschmieter P, Nordheim A, Dittmer J. Transforming growth factor beta regulates parathyroid hormone-related protein expression in MDA-MB-231 breast cancer cells through a novel Smad/Ets synergism. J Biol Chem. 2001;276:46661-46670.
39. Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer. 2000;88:2892-2898.
40. Boyce BF, Yoneda T, Guise TA. Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer. 1999;6:333-347.
41. Goltzman D, Karaplis AC, Kremer R, Rabbani SA. Molecular basis of the spectrum of skeletal complications of neoplasia. Cancer. 2000;88: 2903-2908.
42. Roodman GD. Role of stromal-derived cytokines and growth factors in bone metastasis. Cancer. 2003;97:733-738.
43. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10:789-799.
44. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA. 1992;89:10578-10582.
45. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol. 2003;163:2113-2126. (Pubitemid 37310040)
46. Maroulakou IG, Anver M, Garrett L, Green JE. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci USA. 1994;91:11236-11240.
47. Nielsen LL, Discafani CM, Gurnani M, Tyler RD. Histopathology of salivary and mammary gland tumors in transgenic mice expressing a human Ha-ras oncogene. Cancer Res. 1991;51:3762-3767.
48. Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell. 1987;49:465-475. (Pubitemid 18091823)
49. Hüsemann Y, Klein CA. The analysis of metastasis in transgenic mouse models. Transgenic Res. 2009;18:1-5.
50. Yu Y, Okayasu R, Weil MM, et al. Elevated breast cancer risk in irradiated BALB/c mice associates with unique functional polymorphism of the Prkdc (DNA-dependent protein kinase catalytic subunit) gene. Cancer Res. 2001;61:1820-1824. (Pubitemid 32691991)
51. Mori N, Yamate J, Umesako S, Hong DP, Okumoto M, Nakao R. Preferential induction of mammary tumors in p53 hemizygous BALB/c mice by fractionated irradiation of a sublethal dose of X-rays. J Radiat Res (Tokyo). 2003;44:249-254. (Pubitemid 38738729)
52. Backlund MG, Trasti SL, Backlund DC, Cressman VL, Godfrey V, Koller BH. Impact of ionizing radiation and genetic background on mammary tumorigenesis in p53-deficient mice. Cancer Res. 2001;61:6577-6582. (Pubitemid 32783267)
53. Miller FR, Miller BE, Heppner GH. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invas Metastasis. 1983;3:22-31.
54. Eckhardt BL, Parker BS, van Laar RK, et al. Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol Cancer Res. 2005;3:1-13.
55. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004;117:927-939. (Pubitemid 38798858)
56. Siveen KS, Kuttan G. Role of macrophages in tumour progression. Immunol Lett. 2009;123:97-102.
57. Gabrilovic D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol. 2004;4:941-952.
58. Gallimore A, Godkin A. Regulatory T cells and tumour immunity: observations in mice and men. Immunology. 2008;123:157-163.
59. DeNardo DG, Coussens LM. Inflammation and breast cancer - balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007;9:212.
60. Quaglino E, Mastini C, Forni G, Cavallo F. ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas. Curr Protcol Immunol. 2008;20:20.9.1-20.9.10.
61. Wang CY, Chang YW. A model for osseous metastasis of human breast cancer established by intrafemur injection of the MDAMB-435 cells in nude mice. Anticancer Res. 1997;17:2471-2474. (Pubitemid 27352638)
62. Neuder M, Fischer C, Krempien B, Bauss F, Seibel MJ. Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterization and in vivo effects of ibandronate on tumour growth. Int J Cancer. 2003;107:468-477. (Pubitemid 37266469)
63. Yoneda T, Sasaki A, Dunstan C, et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest. 1997;99:2509-2517. (Pubitemid 27227730)
64. Peyruchaud O, Winding B, Pécheur I, Serre CM, Delmas P, Clézardin P. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res. 2001;16:2027-2034. (Pubitemid 32995393)
65. Canon JR, Roudier M, Bryant R, et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis. 2008;25:119-129.
66. Korpal M, Yan J, Lu X, Xu S, Lerit DA, Kang Y. Imaging transforming growth factor-b signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med. 2009;15:960-966.
67. Price JE, Polyzos A, Zhang RD, Daniels LM. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res. 1990;50:717-721. (Pubitemid 20054204)
68. Li X, Wang J, An Z, et al. Optically imageable metastatic mouse model of human breast cancer. Clin Exp Metastasis. 2002;9:347-350.
69. Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drug. 1999;17:343-359.
70. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449: 557-563.
71. Yang W, Lam P, Kitching R, et al. Breast cancer metastasis in a human bone NOD/SCID mouse model. Cancer Biol Ther. 2007;6: 1289-1294. (Pubitemid 351590385)
72. Moreau JE, Anderson K, Mauney JR, Nguyen T, Kaplan DL, Rosenblatt M. Tissue-engineered bone serves as a target for metastasis ofhuman breast cancer in a mouse model. Cancer Res. 2007;67: 10304-10308. (Pubitemid 350070804)
73. Kim HJ, Kim UJ, Vunjak-Novakovic G, Min BH, Kaplan DL. Influence of macroporous protein scaffolds on bone tissue engineering from bone marrow stem cells. Biomaterials. 2004;26:4442-4452. (Pubitemid 39244392)
74. Li C, Vepari C, Jin HJ, Kim HJ, Kaplan DL. Electrospun silk-BMP-2 scaffolds for bone tissue engineering. Biomaterials. 2006;27:3115-3124. (Pubitemid 43247585)
75. Kuperwasser C, Chavarria T, Wu M, et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Scie USA. 2004;101:4966-4971. (Pubitemid 38469186)